一种四价预防性疫苗，用于预防 HPV-6、-11、-16 和 -18 型感染及相关疾病。

A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.

机构信息

Mount Sinai School of Medicine, 420 West 23rd Sreet, New York, NY, USA.

出版信息

Expert Rev Vaccines. 2012 Apr;11(4):395-406. doi: 10.1586/erv.12.20.

DOI:10.1586/erv.12.20

Abstract

Human papillomavirus infection causes cervical cancer, a significant portion of anal, genital and oropharyngeal cancers, genital warts and recurrent respiratory papillomatosis. In June 2006, a quadrivalent human papillomavirus-6/11/16/18 vaccine (GARDASIL/SILGARD®; Merck, NJ, USA) was licensed in the USA; subsequent approval has been granted in the EU (September 2006). It has since been approved in 121 countries with over 74 million doses distributed globally as of March 2011.

摘要

人乳头瘤病毒感染可引起宫颈癌，还可导致相当一部分肛门癌、生殖器癌和口咽癌、生殖器疣和复发性呼吸道乳头瘤病。2006 年 6 月，一种四价人乳头瘤病毒（HPV6/11/16/18）疫苗（加德西/希瑞适；默克公司，新泽西州，美国）在美国获得许可；随后在欧盟获得批准（2006 年 9 月）。自那时以来，该疫苗已在 121 个国家获得批准，截至 2011 年 3 月，已在全球分发了超过 7400 万剂。